Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hia Glycoconjugate Vaccine in Healthy Adults
NCT06465420Phase 1Active, not recruiting
- Sponsor
- InventVacc Biologicals
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of haemophilus influenzae type a glycoconjugate vaccine in invasive Haemophilus influenzae disease (2 arms), sponsored by InventVacc Biologicals. Primary endpoint: Percentage, intensity, and relationship of adverse events to vaccination at 6 months. Started May 2024; status: active, not recruiting.
02
Drugs
haemophilus influenzae type a glycoconjugate vaccine
03
Conditions
invasive Haemophilus influenzae disease
Beyond the preview
Go deeper on NCT06465420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465420.